Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certepetide plus standard of care in metastatic pancreatic ductal adenocarcinoma
NCT06592664Phase 2Withdrawn
- Sponsor
- Lisata Therapeutics
- Start
- Jan 2030
- Primary completion
- Jan 2035
- Modality
- Cyclic Peptides
01
Overview
Phase 2, randomised, double-blind trial of certepetide in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Lisata Therapeutics. Primary endpoint: Incidence of adverse events. Planned start Jan 2030; status: withdrawn.
02
Drugs
certepetide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06592664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592664.